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Abstract 
A decision to withdraw life‑sustaining treatment (WLST) is derived by a conclusion that further treatment will not ena‑
ble a patient to survive or will not produce a functional outcome with acceptable quality of life that the patient and 
the treating team regard as beneficial. Although many hospitalized patients die under such circumstances, controlled 
donation after the circulatory determination of death (cDCDD) programs have been developed only in a reduced 
number of countries. This International Collaborative Statement aims at expanding cDCDD in the world to help 
countries progress towards self‑sufficiency in transplantation and offer more patients the opportunity of organ dona‑
tion. The Statement addresses three fundamental aspects of the cDCDD pathway. First, it describes the process of 
determining a prognosis that justifies the WLST, a decision that should be prior to and independent of any considera‑
tion of organ donation and in which transplant professionals must not participate. Second, the Statement establishes 
the permanent cessation of circulation to the brain as the standard to determine death by circulatory criteria. Death 
may be declared after an elapsed observation period of 5 min without circulation to the brain, which confirms that 
the absence of circulation to the brain is permanent. Finally, the Statement highlights the value of perfusion repair for 
increasing the success of cDCDD organ transplantation. cDCDD protocols may utilize either in situ or ex situ perfusion 
consistent with the practice of each country. Methods to accomplish the in situ normothermic reperfusion of organs 
must preclude the restoration of brain perfusion to not invalidate the determination of death.
Keywords: Determination of death, Donation after the circulatory determination of death, Normothermic regional 
perfusion, Organ perfusion, Organ repair, Organ transplantation, Tissue and organ procurement, Withdrawal of life‑
sustaining therapy
Background
The World Health Organization (WHO) and The 
Transplantation Society (TTS), a non-governmental 
organization in official relations with the WHO, seek to 
implement the WHO Guiding Principles on the Trans-
plantation of Human Cells, Tissues and Organs [1] 
throughout the world in all countries where deceased 
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organ donation is, or reasonably could be, a component 
of their transplantation programs.
Kidney and liver transplantation are the most frequent 
organ transplants performed (65% and 23% of the annual 
total, respectively) [2]. The WHO has estimated that 
the approximately 147,000 organ transplants performed 
annually meet just 10% of the identified global need [2]. 
Studies of the global burden of disease reveal that this 
need is probably several fold greater, based on the toll 
of disability and of premature loss of life that could be 
prevented by organ transplantation. In many countries, 
transplantation is not offered as a treatment modality 
and access to other treatments for organ failure is lim-
ited. Even in countries with robust transplant programs, 
thousands of patients die or endure a poor quality of life 
while awaiting an organ. This shortage is also the proxi-
mate cause of organ trafficking and transplant tourism, 
practices that violate fundamental human values and 
pose risks to individual and public health [3].
The WHO and TTS have called on countries to pur-
sue self-sufficiency in transplantation by decreasing the 
burden of diseases treatable with transplantation and by 
increasing the availability of organs. But organ transplan-
tation ought not be limited to living donation; indeed, as 
the WHO has stated, priority should be given to deceased 
donation, which should be developed to its maximum 
therapeutic potential [4]. As noted by the WHO, TTS, 
and other stakeholders, such as the International Society 
for Organ Donation and Procurement (ISODP), expand-
ing deceased donation increases opportunity to help 
patients in need by donating organs after death when this 
is consistent with their intention and values.
While in some countries the number of organs trans-
planted from deceased donors far exceeds the number 
contributed by living donors, as of 2018, 10 WHO Mem-
ber States (of more than 80 with transplantation services) 
still relied solely on living donors in liver and kidney 
transplants [2]. In countries where deceased donation 
is practiced, most cases involve donation after the neu-
rological determination of death (DNDD) by physicians 
caring for the donor. This Statement focuses on an alter-
native source of organs from deceased donors, namely, 
donation after the circulatory determination of death 
(DCDD). We note that the terms “donation after cardiac 
death”, “donation after circulatory death” or “non heart 
beating donation” have become obsolete and imprecise. 
Controlled DCDD (cDCDD) refers to organ donation 
from a patient who has died in the hospital following 
the withdrawal of life-sustaining treatment (WLST). We 
recognize that cDCDD has also been proposed follow-
ing euthanasia; however, this paper will not address this 
approach because euthanasia is illegal in most countries. 
Uncontrolled DCDD refers to organ donation following 
failed efforts to resuscitate an individual experiencing 
out-of-hospital or unexpected in-hospital cardiopulmo-
nary arrest.
A decision to WLST is derived by a conclusion that fur-
ther treatment will not enable a patient to survive or will 
not produce a functional outcome with acceptable qual-
ity of life that the patient (or their legal surrogate) and the 
treating team regard as beneficial. Although many hos-
pitalized patients die under such circumstances around 
the world [5], cDCDD programs have been developed 
only in seventeen countries: Australia, Austria, Belgium, 
Canada, China, Czech Republic, France, Ireland, Italy, 
the Netherlands, New Zealand, Norway, Spain, Sweden, 
Switzerland, the United Kingdom, and the United States 
[6, 7]. cDCDD programs are absent in jurisdictions where 
the legislature has not enacted a law providing relevant 
criteria for determining death or professional societies 
have not developed end-of-life care guidelines that sup-
port a pathway to cDCDD [7]. In addition to clinical cri-
teria, such guidelines need to specify how decisions to 
withdraw treatment will be separated from the decision 
that the patient will become an organ donor after death.
Another factor holding back cDCDD is a concern that 
organs recovered from such donors produce inferior 
results for recipients. The number of organs obtained 
from this source has, however, expanded substantially 
during the last decade [2, 7], as the specific injury pat-
terns linking aging and prolonged ischemia of DCDD 
organs are better understood and novel preservation and 
assessment techniques are being implemented. Success 
with cDCDD has now been shown not only with kidneys 
but also with heart, lung, liver, and pancreas transplan-
tation. Moreover, one of the rationales for advancing the 
science of organ preservation is to improve the func-
tion and outcome of organs transplanted from cDCDD 
donors [8]. Increasing the skills of surgeons and ensuring 
their availability both to retrieve deceased donor organs 
and to perform the implantations will also promote 
transplantation in more countries.
A further obstacle to cDCDD in some countries arises 
with deceased donation generally and DNDD. The iden-
tification of potential deceased donors and their referral 
and support until they are declared dead require the use 
of ventilators and other equipment in an intensive care 
unit (ICU), resources that in many countries are not suf-
ficient to care for patients with devastating brain injury 
(DBI). The inadequacy of intensive care, particularly in 
developing countries, may then preclude the develop-
ment of cDCDD—as well as DNDD. This is made evident 
by the association between human development index 
with deceased donation [2].
Doubts about deceased donation among the gen-
eral public also impede the development of cDCDD 
programs. Education is essential if the patients and their 
families are going to understand how death is determined 
and not have concerns when a potential donor is declared 
dead. Having a trained organ donation coordinator avail-
able in the ICU provides a means of answering any ques-
tions from members of a potential donor’s family and 
obtaining permission for organ donation. Although reli-
gious leaders occasionally voice concerns about deceased 
donation, family members can be assured that the prac-
tice is supported by most major religions.
The Algorithm in Fig. 1 displays the pathways by which 
either a DBI that results in a comatose condition or other 
medical events that cause an arrest of cerebral circulation 
can progress to deceased organ donation and transplan-
tation following death determined either by neurologic 
criteria (DNDD) or by the permanent absence of cir-
culation (DCDD) under controlled circumstances. The 
Algorithm highlights three important points along these 
pathways:
  • The process of determining a prognosis that justifies 
the withdrawal of life-sustaining treatment (WLST).
  • Determining death after the permanent cessation of 
circulation to the brain.
  • Perfusion repair for increasing organ transplantation 
success in cDCDD.
The process of determining a prognosis 
that justifies the withdrawal of life‑sustaining 
treatment
The process described in the Algorithm (Fig.  1) reveals 
the transition from a care decision that ongoing life-
supporting treatments can no longer achieve a satisfac-
tory outcome/quality of life for the patient and should be 
withdrawn, to the subsequent presentation of the oppor-
tunity for organ donation after WLST and death. The 
conditions and testing that are detailed in the Statement 
Fig. 1 Algorithm showing the pathways to death and to organ transplantation. ECMO extracorporeal membrane oxygenation, ICU intensive care 
unit, VAD ventricular assist device
are elaborated to reveal the sophistication that has 
evolved to objectively assess prognosis before a decision 
to WLST is made. The decision for WLST is reached 
when continued treatments are not anticipated to enable 
the patient’s survival or an acceptable quality of life [9].
The prognosis leading to a WLST decision should only 
be made by the treating physician in concert with a wider 
multidisciplinary team, subspecialty consults and in dis-
cussion with the patient (if conscious) or the patient’s 
family [10]. The decision for WLST may be informed by 
the presence of an advanced directive refusing extraordi-
nary/invasive measures of treatment. Organ transplant 
and recovery physicians have no role or responsibility in 
the WLST decision.
Conditions in which the WLST is undertaken
The clinical conditions  in which WLST may be under-
taken include (see Algorithm in Fig. 1):
  • Devastating brain injury (DBI).
  • High spinal cord injury.
  • Terminal neurodegenerative disease.
  • Respiratory or heart failure.
These patients may be receiving mechanical ventilation 
and cardiovascular support with vasoactive agents or 
extracorporeal membrane oxygenation (ECMO) or may 
be supported by a ventricular assist device (VAD), as well 
as other support such as renal replacement therapy.
In the Algorithm, the term DBI encompasses patients 
with a neurological condition that is perceived as an 
immediate threat to life or incompatible with satisfactory 
functional recovery and a decision to WLST is being con-
sidered [11]. Souter et  al. have made recommendations 
for the critical care management of patients with DBI 
who have [11]:
  • An acute severe neurological condition, such as pen-
etrating and/or blunt trauma to the brain or ischemic 
stroke, intracranial hemorrhage or anoxic brain 
injury;
  • Been evaluated by a multidisciplinary team including 
neurosurgery and/or neurology expertise;
  • A clinical condition considered to be incompatible 
with survival or an acceptable functional outcome 
not amenable to neurosurgical or other appropriate 
interventions;
  • An ongoing requirement for critical care manage-
ment.
Determining the clinical condition with poor prognosis
In the ICU, WLST becomes an appropriate course for 
patients suffering an unresponsive shock with multiple 
organ failure, with end-stage cardiovascular or res-
piratory failure, and disseminated malignancy. For 
patients with a DBI, clinical experience and repeated 
neurological examination to assess level of conscious-
ness and brain stem reflexes are combined with ancil-
lary investigations which include brain imaging by 
computed tomography (CT) or magnetic resonance 
imaging (MRI), neurophysiology assessments by elec-
troencephalogram (EEG) and evoked potentials, and 
biomarkers such as neuron-specific enolase, to identify 
patients anticipated to die or who have a poor neuro-
logical outcome.
The decision to proceed with WLST is made by a 
medical team with relevant clinical experience utiliz-
ing the available scientific evidence (such as, the cur-
rent prognostic models/scales of severity [12–19]), 
and based on the preferences of the patient, expressed 
personally or by representation. The models pertain-
ing to the development of a prognosis should always 
be used with caution [12–19]; they are not designed 
to be used, and should not solely be used to prognos-
ticate on an individual patient, but assist in informing 
the prognosis. The models have been designed to allow 
benchmarking of units (scales or scores) in outcome 
studies or to allow assessment of new treatments on 
outcome. The models have flaws evident by outcome 
studies where the event prior to death was the WLST 
that can result in a self-fulfilling prophesy, because they 
introduce bias toward a poor prognosis. The historical 
models may also not take into account recent advances 
in treatment. However, the prognostic models (scales 
of severity) are useful in discussions with the patient’s 
family in deciding what course of action best respects 
the preferences and values of that patient. Predicting 
long-term improvement in consciousness and/or cog-
nitive function at the time of hospitalization based on 
statistical modelling may be imprecise in individual 
cases by current diagnostic capabilities. It achieves 
precision only several months or years after the brain 
injury—having waited long enough to determine if the 
prognosis was correct.
Thus, prognostic error may occur either by predicting 
a good prognosis for patients who have a poor outcome 
(e.g. chronically vegetative or minimally conscious state) 
or by predicting a poor prognosis that leads to WLST for 
a patient who could have recovered with a satisfactory 
outcome. Predicting a poor outcome when there could 
have been a recovery is not ascertainable when WLST is 
conducted—because WLST precludes the opportunity of 
recovery.
Finally, biases can cloud the judgment of a physician 
or a healthcare team member, providing a prognostic 
assessment [20]. For example:
  • looking for evidence to support the presumed prog-
nosis rather than contradictory elements;
  • overestimating the likelihood of a prognosis based on 
a recent experience with a similar case;
  • focusing on salient features in the patient’s presenta-
tion too early in the prognosis process and failing to 
adjust this initial impression in light of new informa-
tion.
The decision to WLST generally should be delayed to 
administer appropriate treatment in the ICU for a period 
of up to 72 h [20–22]. This observation period in the ICU 
improves the reliability of establishing a prognosis: in 
determining whether the patient may be declared dead 
by neurological criteria or whose condition is progressing 
to brain death or whether the neurological condition is 
deteriorating (or not improving) and a decision to WLST 
is appropriate. This delay also facilitates the involvement 
of families in decision-making and/or end-of-life care 
planning. In patients who remain comatose after resusci-
tation from an out-of- hospital cardiac arrest, a period of 
up to 72 h for observation and physiological stabilisation 
is also recommended to more precisely identify patients 
who will die or have a poor neurological outcome [21].
Surrogates who may participate in decisions 
regarding life‑sustaining treatment
When a patient is incapable of participating directly in 
treatment decisions, the medical team must turn to a 
surrogate decision-maker who is authorized to make the 
decision on the patient’s behalf. Depending on the juris-
diction, the persons who may serve as a surrogate are 
determined by statute, regulation, judicial decision, or 
custom and typically include:
  • The individual to whom the patient has given a dura-
ble power of attorney to make healthcare decisions;
  • The patient’s spouse or registered domestic partner;
  • The patient’s children who are at least 18 years of age;
  • The patient’s parents;
  • The patient’s siblings;
  • Others with an established relationship to the 
patient;
  • The appointed guardian of any patient.
The hierarchy of surrogates in decision-making varies 
among countries and jurisdictions.
WLST is justified when certain conditions are met
Decision-making at the end-of-life should be based not 
only on patients’ medical prognosis but also on social, 
moral, and welfare considerations [23]. While the cir-
cumstances under which life-sustaining treatment may 
be withdrawn can vary based on local medical, cultural, 
religious traditions, and legal regulations, in many coun-
tries WLST is viewed today as appropriate, based on the 
patient’s prognosis, preferences and values when:
  • Further treatment has become physiologically futile 
because the patient’s hemodynamic, respiratory, 
renal function and their metabolic indices (lactate, 
base excess, pH, renal function) are deteriorating 
despite increasing levels of support;
or
  • The patient could survive with treatment but the 
healthcare team and surrogate decision-maker(s) 
(or patients themselves with certain underlying con-
ditions, e.g., ALS) have concluded that the patient’s 
expected functional outcome and quality of life will 
not be what the patient would want or will not pro-
vide a benefit to the patient that is sufficient to war-
rant the burden of continued treatment;
or
  • When the treating team is made aware of an advance 
directive by the patient that rejects burdensome life-
sustaining treatments.
The location of WLST may have an impact on the dura-
tion of warm ischemia and eventually on post-transplant 
outcomes [24]. However, location and procedures of 
WLST should be developed according to local protocols 
that stress the need to ensure quality in end-of-life care 
and to avoid both over- and under-treatment of pain and 
suffering [25].
Evolving change of end‑of‑life care in the intensive care 
units
Wide variation in end-of-life care practices exists in the 
ICUs throughout the world. This variation was initially 
highlighted by the Ethicus study performed in Europe 
at the beginning of the century [26]. The study revealed 
that WLST was undertaken nearly three times more 
frequently in northern compared to southern European 
countries (47.4% vs 17.9%), while the incidence of brain 
death was nearly four times more frequent in southern 
European countries compared to northern ones (12.4% vs 
3.4%). The ACCORD study, focused on patients who had 
died as a result of a DBI, also made evident differences in 
the frequency of WLST across European countries [27]. 
These differences probably reflected variable professional 
practices that in turn are influenced by cultural, religious 
and social factors in each country.
The Ethicus study has been recently reproduced. Inter-
estingly, while these variations across countries still 
persist, they are less pronounced than previously, with 
more limitations in life-prolonging therapies and fewer 
deaths without treatment limitations, suggesting a shift 
in end-of-life care practices toward WLST in Europe [5].
Separating end‑of‑life decisions from an individual’s choice 
to be an organ donor
The opportunity to participate in deceased dona-
tion should be a routine component in end-of-life care. 
Indeed, those who provide intensive medical care to 
patients near death—including cases where treatment 
withdrawal is being considered—have a responsibility 
to refer such patients to the donation services whenever 
the criteria to do so are met. This principle has been 
endorsed by a number of professional societies con-
cerned with ethical and humane care for patients in the 
ICU [28–30]. Nonetheless, for ethical as well as legal 
reasons, the transition from deciding about the WLST 
to deciding about organ donation needs to be carefully 
managed. The following principles should guide this 
process:
1. The shared decision of the ICU team and the patient 
or surrogate to withdraw treatment should not be 
influenced by the prospect that other persons could 
benefit if the patient’s death made organs available for 
transplantation.
2. The treating team should not raise the possibility 
of cDCDD with the patients or surrogates during 
the discussion of WLST. If the patient or surrogates 
introduce the topic, however, organ donation may be 
addressed during conversations leading to a WLST 
decision. The team should also ascertain that the 
decision of WLST is supported regardless of the pos-
sibility of cDCDD.
3. Once a WLST decision has been reached, the treat-
ing physicians may work with the organ donation 
team to raise the possibility of donation with the 
patient or surrogate and to facilitate donation when 
that is appropriate given the patient’s medical condi-
tion and is consistent with the patient´s wishes and 
values. In some countries, people are able to record 
a legally recognized decision to donate through a 
donor registry. Registries and the other legal and 
regulatory mechanisms provide the ethical benefit of 
allowing donors to make donation decisions them-
selves while they are still able to do so [31]. During 
the donation conversation with family, information 
should be conveyed that the donation may not pro-
ceed finally because of medical unsuitability (e.g. 
malignancy, infection, death not occurring within a 
timeframe that permits organ transplantation).
4. To avoid creating a conflict of interest or the per-
ception of such a conflict, the physicians involved in 
caring for the patient, in deciding to withdraw treat-
ment, in managing the withdrawal, and in declaring 
death must not currently be involved in caring for 
the potential recipients of the donated organs as they 
await the transplant or in transplanting those organs.
5. As discussed previously, the limits to prognostic 
certainty must be candidly discussed with all deci-
sion-makers, including the healthcare team and the 
patient or surrogate. These limits apply whether 
decision for WLST is accompanied by a decision for 
cDCDD—or not and do not become more grave or 
problematic when a WLST decision is followed by 
cDCDD.
Every day in ICUs around the world patients die fol-
lowing the WLST. Yet in the many countries that lack 
cDCDD programs, the autonomy of such patients and 
their families regarding final bodily disposition after 
death is diminished, because they are not offered an 
opportunity to donate organs. In addition, by preclud-
ing treating physicians from raising the opportunity for 
cDCDD once a decision to withdraw life-support has 
been made, these countries reduce the number of organs 
available for transplantation and thus undermine national 
efforts to achieve self-sufficiency in organ donation and 
transplantation.
Recommendations pertaining to the process of determining a prog‑
nosis that justifies the withdrawal of life‑sustaining treatment
Health authorities, professionals and professional associations should 
evaluate the circumstances of patients dying in ICUs. In countries 
where WLST is an accepted practice in the consideration of treatment 
futility and end‑of‑life care, the possibility of developing a cDCDD 
program as a routine component of end‑of‑life care should be 
explored
The cDCDD program must be developed with a comprehensive regu‑
latory framework that emphasizes the independence of decisions 
related to the WLST from the consideration of organ donation
Transplant healthcare professionals must not be involved in reach‑
ing the decision to WLST nor in the actions involved in the WLST
Determining death after the permanent cessation 
of circulation to the brain
Unifying concept of death
The principal consequences of the loss of brain func-
tions—namely, that the person loses both conscious-
ness and all brainstem reflexes including the capacity to 
breathe—explain why the permanent cessation of brain 
function provides the unifying concept of human death 
[32, 33]. Whether the primary pathophysiology is cer-
ebral circulatory arrest or direct DBI, and whether the 
loss of brain function is measured through neurological 
examination or by ascertaining the permanent cessation 
of circulation to the brain, loss of brain functions is the 
ultimate criterion for determining death.
Determining death
Permanent cessation of the capacity for consciousness 
and of the capacity to breathe and all other brainstem 
functions can arise directly from an injury to the brain or 
indirectly when circulation to the brain has been inter-
rupted. Determining death by the permanent cessation 
of brain function is consistent with the medical standards 
for determining death outside the context of organ dona-
tion [34, 35]. Death can be confirmed by circulatory cri-
teria when there is:
  • No forward circulatory flow to the brain;
  • No perfusion of brain cells; and
  • Loss of capacity for consciousness, of capacity to 
breathe, and of all other brainstem functions.
In those countries and jurisdictions where the deter-
mination of death by neurologic criteria is not cur-
rently accepted, then death determined by a permanent 
absence of circulation after a decision for WLST should 
be considered.
The relationship between WLST, circulatory arrest 
and brain function
The relationship between WLST, circulatory arrest and 
death determined by the permanent cessation of brain 
function is diagrammed in Fig. 2.
When life-sustaining therapies are withdrawn (see the 
Algorithm in Fig.  1) following a decision that ongoing 
life-supporting treatments are no longer in the patient’s 
best interest (see Sect. 1), death may be determined after 
the cessation of circulation. With cessation of systemic 
circulation, all blood flow to the brain ceases followed 
quickly by cessation of all brain electrical activity. The 
EEG (a surrogate of brain activity) becomes isoelectric 
within 30 s of abrupt arrest of circulation or flow to the 
brain [36]. Nevertheless, the existing evidence is insuffi-
cient to:
  • Resolve how long the circulation to the brain must 
be arrested before brain function is irreversibly lost 
(cannot resume under any circumstance), i.e. the 
time after circulatory arrest by which brain func-
tion cannot resume if brain flow and perfusion are 
restored;
  • Understand what amount of circulation (pressure, 
flow) is sufficient to generate brain perfusion and 
how much brain perfusion is required to generate a 
restoration of brain function.
In the circumstance of WLST, when hypoxia/hypo-
tension precedes cardiac arrest, isoelectric EEG may 
occur prior to the arrest of circulation [36, 37].
If there is no attempt to restart systemic circulation, 
the permanent cessation of circulation to the brain leads 
inevitably to permanent cessation of brain function. If 
circulation is restored, brain function might be restored. 
In animal studies, the longest documented time for com-
plete restoration of neurologic activity in a canine model 
following sudden cardiac arrest is 11 min [38]. In experi-
ments using a cytoprotective perfusate, cellular activity 
has been restored in pig brains up to 4  h after decapi-
tation [39]. Despite the cellular activity, the pig brains 
exhibited no function as demonstrated by EEG or elec-
trocorticogram nor recovery of the integrated brain func-
tions necessary for consciousness. This study highlights 
Fig. 2 Death determined by the permanent cessation of brain function. The x axis in time is not linear. The time that elapses from 5 min when 
death is declared by the permanent absence of circulation to an assured irreversibility of brain functions is in hours. DCDD donation after the circu‑
latory determination of death, WLST withdrawal of life‑sustaining therapy
the distinction between brain cellular activity and brain 
function relevant to determining death in human beings 
[40].
Irreversible versus permanent cessation
An irreversible cessation of circulation (cannot be 
reversed) necessarily means that the cessation is per-
manent, that is, lasting or intended to last or remain 
unchanged indefinitely. A cessation of circulation that is 
not irreversible is permanent if it occurs under circum-
stances, such as WLST, when no effort will be made to 
restore circulation to the brain and the point in time has 
passed when circulation could resume spontaneously 
[41–43].
When measurement of brain functions is used to deter-
mine death, the cessation of neurological functions must 
be irreversible but, as just noted, the circulatory standard 
requires the cessation to be permanent but not necessar-
ily irreversible. This difference exists, because so-called 
“brain death” was developed as a retrospective deter-
mination attesting to functional loss in the brain that 
occurred earlier (whether from an injury or in the clinical 
course of care). By the time death is determined on this 
basis, the cessation of brain functions is clearly irrevers-
ible due to the time that has elapsed since the insult. In 
contrast, in the context of WLST, circulatory death deter-
minations are made in real time, with death declared at 
the point of permanent cessation which may be before 
the loss of brain functions has become irreversible [34, 
44].
Following systemic circulatory cessation, when there 
is no intent to attempt resuscitation (such as in patients 
who have a do not attempt resuscitation order or as 
occurs in cDCDD), and the possibility of auto-resus-
citation has been excluded, death is defined as the per-
manent loss of capacity for consciousness and loss of all 
brainstem functions, determined by the permanent ces-
sation of circulation to the brain [44].
Requisites to determine death after life‑sustaining 
treatment is withdrawn in a cDCDD protocol
1. Verify that the decision not to attempt resuscitation 
after circulatory arrest is documented in the medical 
record
2. Verify that circulatory cessation has occurred
 The absence of systemic circulation must be reliably 
established by a validated test such as:
• Absence of arterial pulsations observed by an 
indwelling arterial line or absence of continuous 
flow generated by a ventricular assist device or 
extracorporeal circuit;
•  Absence of opening of the aortic valve by echocar-
diography.
•  Absence of circulation by arterial Doppler studies;
•  Absence of electrical activity on an electrocardio-
gram;
 All these tests are appropriate to verify the cessa-
tion of circulation, though preference should be 
given to non-pulsatile arterial line monitoring. In 
the absence of a functioning arterial line, second-
ary options would be echocardiogram, Doppler, 
or electrocardiography. The use of an electro-
cardiogram to assess the cessation of circulation 
may unnecessarily prolong warm ischemia, since 
electrical activity can persist with no effective 
circulation.
3. Verify that the time for possible auto-resuscitation has 
elapsed
 An international collaborative prospective study has 
been recently conducted in Canada, United King-
dom, and Czech Republic to describe outcomes fol-
lowing the decision to WLST and not to provide 
cardiopulmonary resuscitation: 69 of 480 patients 
(14%) were observed to have an unassisted return 
of circulation (as defined by a single pulse pres-
sure ≥ 5 mmHg) up to 4 min and 20 s after the obser-
vation of asystole [45]. None was observed to have 
circulation beyond 5 min and all patients died.
 The presence of one heartbeat within 60 s that results 
in a pulse pressure of > 5 mmHg is a proposed crite-
rion of determining a resumption of circulation that 
can be used to define auto-resuscitation after circu-
latory arrest in cDCDD; however, this criterion is a 
surrogate of circulation which does not truly meas-
ure whether circulation or brain perfusion are occur-
ring. If circulation does return in accordance with 
this definition during the observation period, the 
observation period must be recommenced.
Since the cessation of brain function results from the 
permanent cessation of blood flow to the brain, neuro-
logical examinations, of the sort used in DNDD, are not 
performed in cDCDD [46].
It also follows that the decision to withdraw treatment 
and permit death to occur entails prohibiting any inter-
vention, such as cardiopulmonary resuscitation, that could 
restore brain circulation after death has been declared. 
Methods to accomplish in situ normothermic reperfusion 
of organs must, therefore, be targeted to preserving the 
organs intended for transplantation, while precluding the 
restoration of brain perfusion [47, 48].
Lung reinflation performed during cDCDD lung recov-
ery could be associated with the resumption of cardiac 
activity and after the 5-min period of asystole that enabled 
a declaration of death. Therefore, lung reinflation intended 
to minimize warm ischemic time (WIT) of the lungs 
should be performed only when there is certainty that a 
spontaneous resumption of cardiac activity will not occur. 
The protocol for lung cDCDD in the United Kingdom 
addresses this issue by delaying this maneuver until a mini-
mum of 10  min after loss of the circulation has elapsed, 
allowing only a single vital capacity inflation of the lung, 
followed by the application of continuous positive airway 
pressure or clamping of the endotracheal tube [49]. Cyclical 
ventilation is avoided until the surgical team has started to 
flush the lungs and has vented the left atrium. Alternatively, 
lung reinflation can be delayed until the administration of 
cardioplegia (in combined heart and lung cDCDD recov-
ery) or until the pulmonary artery is cannulated and the 
preservation effluent is being drained through an opened 
left atrium. Both maneuvers render the heart incapable of 
coordinated contraction.
The observation period
A period of time must be established for observation of 
the patient after treatment is withdrawn and circulation 
has ceased to witness that auto-resuscitation of circula-
tion has not occurred, and to ensure that the intention not 
to attempt resuscitation has been honored. Because auto-
resuscitation can occur within the first 5  min following 
circulatory arrest, this observation period should not be 
< 5 min [45]. Once this period has passed, a physician (or 
more than one, when legally required) who is independ-
ent of the organ recovery team and of any clinical duties to 
potential recipients of the organs may declare death based 
on the permanent absence of circulation in the patient.
Recommendation pertaining to determining death after the perma‑
nent cessation of circulation to the brain
In cDCDD, death may be declared after an elapsed observation period 
of 5 min without circulation which confirms that the absence of 
circulation is permanent. The permanent absence of circulation to the 
brain results in the permanent absence of brain functions
Transplant professionals caring for potential transplant recipients 
should not be involved in the determination of death
Perfusion repair for increasing organ 
transplantation success in cDCDD
The period of donor warm ischemia inherent to the 
cDCDD process, related to progressing hypoxemia and 
hypotension after WLST, can damage organs intended 
for transplantation and the liver and heart in particu-
lar, since the biliary and myocardial cells are highly sus-
ceptible to warm ischemia [50]. Initial experiences with 
DCDD liver transplantation described high rates of graft 
dysfunction and non-function and of ischemic type bil-
iary lesions (ITBL). Although complication rates have 
decreased in frequency with experience, the rate of 
post-transplant ITBL remains higher among recipients 
of DCDD grafts vs those obtained from DNDD donors 
[51, 52]. Development of ITBL leads to repeat biliary pro-
cedures and hospitalizations; up to 70% of patients with 
ITBL either require re-transplantation or die [53]. Kidney 
transplants from cDCDD donors exhibit a higher inci-
dence of delayed graft function (DGF), with similar graft 
survival and function in the short and mid-term [54].
Innovative approaches for the perfusion of organs 
recovered for transplantation are underway by ex situ 
(outside the body) machine perfusion of individual 
deceased donor organs and in  situ (inside the body) 
regional perfusion of thoracic and abdominal organs in 
the deceased donor (see the Algorithm Fig. 1). Appropri-
ate post-transplant outcomes have been accomplished 
with cDCDD kidneys and lungs without the necessity of 
dynamic perfusion strategies. Hence, developing coun-
tries need not presume that sophisticated preservation 
technology is a requirement for successful cDCDD kid-
ney transplantation. Nevertheless, strategies of perfusion 
and repair are essential for cDCDD liver transplantation 
because of the complications that occur following cold 
storage of the liver, and to make cDCDD heart transplan-
tation possible.
This section summarizes these recent advancements 
without preferentially recommending the approaches 
that are described.
Ex situ organ preservation and repair
Ex situ liver perfusion and repair
Most promising and actively explored methods of ex 
situ machine perfusion of livers include hypothermic 
oxygenated machine perfusion (HMP) and normother-
mic machine perfusion (NMP). Both modalities can be 
applied either to replace static cold storage or after static 
cold storage at the center (post-ischemic) performing the 
transplant [55]. While HMP reduces ischemia–reper-
fusion injury of DCDD grafts and may reduce the inci-
dence of (biliary) complications after transplantation, 
NMP enables ex situ assessment of hepatobiliary viabil-
ity of cDCDD livers prior to transplantation. In contrast 
to HMP, end-ischemic NMP has not yet been proven to 
reduce biliary complications [56, 57]. However, this tech-
nique may increase the number of transplanted organs 
through ex situ assessment and improve the condition of 
injured or marginal liver allografts [58, 59].
Ex situ heart perfusion and repair
Beginning with the first heart transplant performed by 
Christiaan Barnard in 1967, early transplants utilized 
DCDD hearts from donors who were in the same hospital 
as their recipients. Within several years, however, trans-
plantation came to rely solely on DNDD hearts. Then, 
in 2014, a group in Sydney began a series of transplants 
using extracorporeal perfusion to maintain the viabil-
ity of distantly procured cDCDD hearts [60], a practice 
now used for some transplants by a number of hospitals 
not only in Australia but also in the United Kingdom, 
and the United States (eTable 1). Recently, teams at other 
hospitals have begun transplanting cDCDD hearts from 
donors co-located with recipients, using thoraco-abdom-
inal normothermic regional perfusion (TA-NRP), with-
out extracorporeal perfusion (eTable  1). In total, more 
than 150 transplants have been performed in the past 6 
years with cDCDD hearts.
Accepting that the heart is very sensitive to ischemia 
[61], both cold and warm—so that it is generally required 
that DNDD hearts be re-perfused for under 4 h of cold 
ischemia—several factors pertinent to the cDCDD pro-
cess should be addressed before embarking upon a pro-
gram of cDCDD heart transplantation:
  • The administration of heparin. The ability to give 
heparin prior to death remains variable across coun-
tries. Few jurisdictions permit ante mortem cannula-
tion (only Belgium and Spain in Europe). Some per-
mit ante mortem identification of the femoral vessels 
to facilitate cannulation post-circulatory death deter-
mination (e.g. France, Italy and Norway) [7].
  • The no-touch period between asystole to the decla-
ration of death varies in time amongst the countries 
that practice cDCDD.
  • WIT is marked by hypoxia, ischemia, hypoperfusion 
and cardiac distension culminating in warm ischemic 
injury that has been the major obstacle in limiting the 
uptake of cDCDD heart transplantation. The degree 
of ischemic injury and the ensuing ischemia–reper-
fusion injury correlates with DGF following trans-
plantation. The Australian data suggest that limiting 
the time from asystole to cardioplegia delivery would 
limit the need for post-transplant mechanical circu-
latory support [62].
The original Sydney protocol describes a rapid 
retrieval process with subsequent instrumentation of 
the donor heart on to a perfusion device for ex situ 
reanimation. The only device that currently permits 
continuous perfusion and assessment of myocar-
dial viability is the Organ Care System (OCS™-Heart, 
TransMedics Inc, USA). It allows the beating donor 
heart to be transported in a normothermic blood-based 
perfusion with physiological measurements of aortic 
pressure, coronary flow, cardiac rhythm, haematocrit 
and additionally by measuring the arterio-venous lac-
tate level as a metabolic marker of myocardial health. 
A down-trending lactate level with evidence of lac-
tate absorption is indicative of satisfactory myocar-
dial reserve if the other physiological parameters are 
also normal [60]. In Australia, the Sydney protocol 
is the only permissible cDCDD heart retrieval pro-
cess because the country’s definition of death does 
not permit in  situ restarting of the circulation. It has 
also become the preferred method for the majority 
of cDCDD heart transplant programs. The Papworth 
group has described an alternative approach of normo-
thermic regional perfusion (NRP) that involves cannu-
lation for extracorporeal driven circulation and in  situ 
reanimation of the heart [63]. This approach permits 
the in  situ assessment of the heart before cardioplegic 
arrest. Nevertheless, the Papworth group also performs 
heart recovery directly without NRP.
Devices for continuous cold perfusion which lessen 
the logistical burden during transportation are likely to 
be in clinical trials soon and these will require an addi-
tional working modality device for functional assess-
ment prior to transplantation [64].
The outcomes from cDCDD heart transplanta-
tion out to the medium term have been excellent. The 
Sydney experience at five and a half years consists of 
43 cDCDD heart transplants of which 10 recipients 
required post-implant ECMO for DGF. This require-
ment for mechanical circulatory support was over 30% 
during the earlier phase but is currently running at < 
15%. The all-cause survival is 98% at 1-year and 95% at 
5-years (personal communication). Similar outcomes 
have been reported from the higher volume program 
at Papworth Hospital, which reported on its first 79 
cDCDD heart transplants with a 30-day survival of 97% 
vs 99% for the matched DNDD cohort. In the cDCDD 
heart transplant group, no significant differences in 
survival were found between 22 recipients included in 
the NRP protocol and 57 in the rapid recovery protocol 
[65].
cDCDD heart transplantation has become part of 
standard practice of care in the few pioneering centers in 
Australia and the UK. Their excellent results at medium 
term [62, 65] and the recent commencement of simi-
lar programs in North America and continental Europe 
should broaden and accelerate the uptake of cDCDD 
heart transplantation.
Coordination of heart and liver recovery in cDCDD
Heart recovery requires ~ 1500  mL of donor blood to 
prime the ex situ preservation pump (OCS™-Heart 
device). The collection of this donor blood from the right 
atrium requires attention to the differences in WIT that 
are computed for the heart versus the liver. WIT for the 
liver commences at the time of extubation. The donor 
heart’s functional WIT starts when the  SpO2 falls below 
70% or the systolic blood pressure goes below 50 mmHg. 
This calculated difference may enable a cDCDD heart 
recovery more than 30 min after extubation (but not the 
liver). For cDCDD liver recovery, cold perfusion of the 
abdominal organs with a cross-clamp of the aorta at the 
diaphragm should be initiated before 30  min following 
extubation. Thus, if the patient is declared dead between 
20 and 25  min following extubation, the maneuvers to 
enable extraction of right atrial blood for the heart and 
installation of cardioplegia to the coronary arteries and 
perfusion of the liver must be coordinated carefully—not 
to exceed 30 min following extubation for successful liver 
recovery.
Ex situ lung perfusion and repair
Amongst all solid organs, the lung is unique in the capac-
ity of ex situ perfusion to repair or improve the function 
of a deceased donor lung, as pulmonary cells can survive 
for hours after the absence of oxygenated blood circula-
tion. Continued aerobic metabolism is based on paren-
chymal oxygen reserve delivered via a mechanism of 
passive diffusion through the alveoli. This tolerance to 
warm ischemic injury makes the lung a privileged organ 
in the setting of DCDD.
Normothermic ex situ lung perfusion was clinically 
introduced as a platform to preserve, assess and recon-
dition lungs after recovery from the donor prior to 
transplantation [66, 67]. This technique was originally 
pioneered by Stig Steen (Lund, Sweden) [68] and further 
developed by the Toronto group as a clinical tool to (re)
evaluate the function of the pulmonary allograft that may 
have suffered considerable injury during the process of 
organ donation [69, 70]. Several commercial devices for 
machine lung perfusion are currently available [71].
Several series from individual institutions and national 
organizations have now reported comparable early- and 
medium-term recipient outcomes after lung transplanta-
tion from cDCDD versus standard DNDD donors [72]. 
The largest experience with cDCDD comes from the 
DCDD Registry by the International Society for Heart 
and Lung Transplantation (ISHLT) with 22 participat-
ing institutions worldwide. Lung transplantation from 
cDCDD donors yielded excellent 5-year survival identical 
to DNDD donors [73].
In the ISHLT DCDD Registry Statement, only 15% of 
DCDD allografts underwent pre-transplant assessment 
by normothermic ex situ lung perfusion with the majority 
of such cases done at one institution [73]. This low per-
centage likely reflects the perception of each participating 
center of the real need or benefit of ex situ lung perfu-
sion in assessing lungs from cDCDD donors. Excellent 
outcomes after transplantation of lungs from cDCDD 
donors have been reported without ex situ lung perfusion 
[73]. The majority of the DCDD donors in the ISHLT 
Registry (84.5%) suffered an agonal phase ≤ 30 min from 
WLST to cardiac arrest and 90% of DCDD lungs had a 
functional warm ischemic time (WIT) ≤ 30  min from 
arterial blood pressure < 50 mmHg until cold pulmonary 
flush [74], indicating that the risk for injury prior to cold 
preservation was limited in time. Therefore, the utility of 
ex situ lung perfusion for cDCDD lung transplantation 
may be selectively indicated in donors with an extended 
agonal period or WIT of > 30 min.
The ability to perfuse lungs for a period of time to 
assess function of questionable donor lungs has already 
significantly increased donor utilization [70]. Vari-
ous technologies and techniques for ex situ lung perfu-
sion (as well as the mode of application in the various 
categories of DCDD donors) continue to evolve as this 
concept has achieved increasing traction in clinical pro-
grams around the world. The application of ex situ lung 
perfusion for DCDD lungs has facilitated the use of this 
growing source of organ donors. The promise of ex situ 
lung perfusion lies in the ability to assess, treat and pre-
condition organs prior to transplant to achieve improved 
donor utilization with superior short and long-term post-
transplant outcomes.
Ex situ kidney perfusion and repair
The first Statement of NMP in kidney transplantation 
began in Leicester, UK with a series of 28 extended-cri-
teria donors and 8 cDCDD kidneys. Circulating a red 
cell-based solution through the kidney allograft at near 
normal temperature for a brief 1-h period prior to trans-
plantation reduced the rate of DGF from 36 to 11% in 
this cohort of patients. A standard cardiac pulmonary 
bypass technology was adapted to perfuse an isolated 
kidney [75].
A randomized controlled trial (Trial number: 
ISRCTN15821205) to assess the effects of 1 h NMP com-
pared to static cold storage in DCDD kidney transplan-
tation has completed recruitment and will be reported 
in 2021. The primary end point is the rate of DGF in the 
first 7 days after transplantation. Four UK transplant cen-
tres have participated in the trial (Cambridge, London, 
Newcastle and Edinburgh).
NMP can also be used as a device to test the quality of 
a kidney prior to transplantation. A particular advantage 
is the assessment of the microvasculature in DCDD kid-
neys that have been inadequately flushed at retrieval. The 
Leicester group is running a programme using NMP to 
retrieve and assess kidneys that have been discarded on 
this basis. A total of 21 kidneys have been assessed, 11 of 
these were successfully transplanted [75].
The results of the randomized trial will inform clinical 
practice for DCDD kidney transplants in the future. It is 
also likely that the technology will be used as an assess-
ment device and as a platform for the delivery of thera-
peutic agents.
In situ organ preservation and repair
NRP has emerged as a strategy to reperfuse and reoxy-
genate organs in  situ using an ECMO device, following 
the determination of death by circulatory criteria and 
before organ recovery. NRP is now routinely applied in 
cDCDD in France, Italy, Spain and the UK, and is being 
piloted in Belgium, the Netherlands, Norway, and Swit-
zerland [7].
Abdominal NRP with ante mortem vessel cannulation
If the national legal framework allows ante mortem inter-
ventions in the body of a prospective cDCDD donor, spe-
cific informed consent should be obtained. Ante mortem 
cannulation of femoral vessels can be performed open or 
percutaneously. In some countries, the process of iden-
tifying the femoral vessels occurs prior to the WLST, 
but cannulation is completed after the determination of 
death [7]. A deflated aortic occlusion balloon is placed 
through the contralateral femoral artery and is advanced 
into the supraceliac aorta under radiographic control [76, 
77].
Once death is declared (see the Algorithm in Fig.  1), 
the thoracic aortic balloon is inflated and abdominal 
NRP (A-NRP) is started, directing oxygenated blood to 
those organs to be recovered for transplantation and iso-
lating brain circulation [74–78]. Two arterial lines, one 
from the femoral arterial cannula and the second from 
the left radial artery should be monitored during A-NRP 
to ensure blocking of the aorta [48, 76]. With occlusion of 
the aorta technically assured, the arterial pressure from 
the left radial artery will be absent, while the pressure 
from the femoral arterial cannula is maintained as a con-
tinuous, non-pulsatile pressure, as it is provided by the 
ECMO device.
Blood samples from the ECMO device are obtained just 
after starting A-NRP and at least every 30 min to monitor 
biochemical, haematological and acid–base parameters. 
Hepatic transaminases should remain stable throughout 
A-NRP. Transaminases more than three times the upper 
normal value at baseline and/or more than four times the 
upper normal limit at the end of A-NRP are considered 
a relative contraindication for liver transplantation [77–
80]. A decrease of the initial lactate levels (following 30 
and 60 min of A-NRP) may also be a good biomarker of 
an adequate perfusion of organs [78, 81]. A-NRP is run 
for 90–120 min to allow the adequate reconditioning of 
abdominal organs.
Abdominal NRP with post‑mortem vessel cannulation
Once death is declared, the surgical team cannulates the 
abdominal aorta and the infrarenal vena cava. The supra-
coeliac aorta is clamped and then A-NRP is initiated and 
managed as previously described [79].
Thoraco‑abdominal NRP
Thoraco-abdominal NRP (TA-NRP) was first used in the 
UK to allow the successful recovery and transplantation 
of cDCDD donor hearts [63]. Following the declaration 
of death, a sternotomy is performed and the supra-aortic 
vessels are clamped to direct preservation fluid to organs 
to be recovered for transplantation (and isolate brain 
circulation). Recently, a refinement to current protocols 
has been proposed to ensure that circulation to the brain 
through collateral circulation does not occur during TA-
NRP [47]. TA-NRP is then commenced and mechanical 
ventilation is also restarted. The heart is inspected after 
return of sinus rhythm within the cDCDD donor after 
weaning off TA-NRP, relying on the heart to perfuse 
the thoracic and abdominal organs. The donor heart is 
assessed clinically and by pulmonary artery catheter (car-
diac output and atrial filling pressures), transoesopha-
geal echocardiography and visual inspection. Heart is 
then recovered using a similar approach to the one in the 
DNDD setting.
In the Papworth technique, TA-NRP is followed by 
instrumentation on the OCS™-Heart device for trans-
portation [82]. Successes with the TA-NRP technique fol-
lowed by cold preservation and storage for transport have 
recently been reported by two teams in Belgium (Liège, 
Leuven) [83, 84] and three centers in Spain [85, 86].
Results of transplants from cDCDD donors subject to NRP
Based on data from preclinical and clinical studies, NRP 
seems to reverse the metabolic derangements caused by 
warm ischemia, re-establishing cellular physiology after 
energetic depletion and clearing metabolites [87]. This 
preconditioning effect of NRP may attenuate ischemia–
reperfusion injury. NRP allows to transform an urgent 
into an elective recovery procedure, similar to the one in 
the context of DNDD [79, 80]. During NRP, an evaluation 
of organ viability can take place based on the behavior of 
certain biochemical parameters, as already mentioned.
Two recently published multicenter retrospective expe-
riences have shown the benefits of NRP in liver trans-
plantation from cDCDD donors [77, 79]. Both studies 
reveal that, compared with the standard rapid recovery 
technique, NRP is associated with a decreased rate of 
overall biliary complications, ITBL, and graft loss. The 
experiences also show that donor age of cDCDD liver 
donors could be expanded safely with NRP, as suggested 
by other authors [78]. The superior outcomes of NRP 
suggested by these reports need to be confirmed in rand-
omized controlled trials [88].
Information on the impact of NRP on cDCDD kidney 
transplantation is scarce. Spanish data suggest that NRP 
is associated with a significantly lower incidence of DGF, 
but with no significant benefits in terms of primary non-
function and graft survival in the short-term [89]. Some 
preliminary favorable results have also been published 
regarding pancreas transplantation in cDCDD with the 
use of NRP, but the experience is still limited [75, 90].
TA-NRP is being used in the UK, Belgium, and more 
recently in Spain as a strategy to allow the validation and 
preservation of hearts of cDCDD donors [63, 83–86]. In 
the British experience, most hearts recovered by using 
TA-NRP have been followed by ex situ machine per-
fusion. Eight heart transplant procedures have taken 
place in the world with the use of TA-NRP without ex 
situ machine perfusion. Given the high cost of ex situ 
machine perfusion, unaffordable in many settings, TA-
NRP may become a way of making heart transplanta-
tion from cDCDD donors economically feasible in some 
countries.
The impact of TA-NRP on cDCDD lung transplan-
tation is currently unknown. It is important to under-
stand that with the technique of TA-NRP, the lungs will 
not receive antegrade perfusion through the pulmonary 
arteries until the arrested heart starts beating again. 
However, the lungs will receive limited flow of oxygen-
ated blood via the bronchial circulation originating from 
the descending aorta. Therefore, in the setting of A-NRP 
using a clamp on the descending aorta, or in cases where 
the heart does not generate sufficient cardiac output dur-
ing TA-NRP, lungs will not be perfused while remaining 
normothermic.
Re‑establishment of regional circulation after determining 
death in cDCDD
NRP poses not only technical, but also ethical chal-
lenges. The most critical one is the possibility that cir-
culation to the brain is inadvertently restored during 
NRP—which would retroactively negate the diagnosis 
of death by circulatory criteria. According to the uni-
fying concept of death in the cDCDD context, when 
systemic circulation ceases, the relevant loss is the 
permanent cessation of circulation to the brain. The 
consequence of this lack of circulation is that the brain 
undergoes ischemic infarction, with the inevitable loss 
of brain function (Fig. 2). Thus, restoration of oxygen-
ated blood flow to the thorax and abdomen when using 
NRP must exclude all circulation to the brain since the 
resumption of systemic circulation would otherwise 
be inconsistent with a declaration of death. Restoring 
brain circulation would invalidate the death determi-
nation because the unifying concept of death requires 
brain circulation to have ceased indefinitely, resulting 
in the permanent cessation of brain function [91]
Techniques used for isolating the brain in A-NRP 
include a balloon occlusion or surgical clamping of the 
thoracic aorta, which can be monitored by the absence 
of constant pressure at the radial artery [48] or by the 
lack of flow from a cannula inserted in the ascending 
aorta and open to the atmosphere [47]. When TA-NRP 
is used, isolation of brain circulation may be achieved 
by the clamping of the aortic arch vessels. Importantly, 
the free drainage of the aortic arch vessels to atmos-
pheric or negative pressure diverts collateral blood flow 
away from the brain [47]. To exclude arterial anatomi-
cal variants, ante mortem tests to visualize cerebral 
circulation (e.g. angiography) may also be considered. 
Given the complexity of techniques to ensure absence 
of circulation to the brain during TA-NRP, this should 
only be performed in the context of specific research 
protocols by teams with sufficient training and exper-
tise. Monitoring absence of brain circulation (perfusion 
or function) during TA-NRP is an essential component 
of such protocols.
Occluding the thoracic aorta or the aortic arch vessels 
to deliberately exclude brain circulation raises two con-
cerns: (i) the involvement of the recovery surgeon in the 
patient´s death, and (ii) the use of an invasive interven-
tion solely to satisfy the permanence of the cessation of 
brain functions.
As to the first concern, the intentional exclusion of 
brain circulation by use of isolation techniques is not 
the cause of death. The cause of death is the DBI or the 
underlying disease that led to the decision to WLST. 
Moreover, the surgeon who occludes the thoracic aorta 
or the aortic arch vessels in order to perfuse the trans-
plantable organs no more causes the death of the donor 
than does the surgeon who recovers a heart for trans-
plantation after a donor has been declared dead. As to the 
second concern, the use of techniques to prevent brain 
perfusion respect two decisions made by the  donor or 
their surrogate: first, the decision not to be resuscitated 
after the declaration of death which entails the intention 
that circulation not be restored to the brain, and sec-
ond, the decision to benefit patients in need of donated 
organs, which entails the taking of steps to maximize the 
functioning of the transplanted organs.
Recommendation pertaining to perfusion repair for increasing 
organ transplantation success in cDCDD
The value of perfusion repair for increasing the success of organ trans‑
plantation is established by this Conference Statement to recom‑
mend that a protocol of cDCDD utilize either in situ or ex situ 
perfusion consistent with the practice of each country conducting 
cDCDD
Overall recommendations as a result of these 
consensus deliberations
  • The Conference Statement and Algorithm should 
be published in the medical literature as a refer-
ence guide for either the initiation or expansion of 
cDCDD.
  • A review of the Conference Statement by the WHO 
Task Force on Organ Donation and Transplantation 
is requested to subsequently seek the endorsement 
of the WHO in promoting cDCDD to all Member 
States.
  • A common terminology should be used for all types 
of donors and perfusion techniques to avoid confu-
sion amongst professionals and the public.
  • The expansion of cDCDD should be a component of 
the proposed WHO Global Consultation on the sci-
ence of organ donation and transplantation.
  • The International Professional Societies should be 
engaged to disseminate the Conference Statement 
and aligned Algorithm to provide education for 
members.
  • The Algorithm should be submitted to professional 
society meetings for presentation.
  • A cDCDD Committee should be developed inclusive 
of the professional expertise that has developed the 
Conference Statement and Algorithm to accomplish 
these tasks.
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